Stephan Stilgenbauer

ocupació: investigador

Sèrie

There is nothing here

Create a new serie

Treballs

There is nothing here

Create a new work

Articles 311

Date

Títol

Autors

2020-07-23

Insertion site of central venous catheter correlates with catheter-related infectious events in patients undergoing intensive chemotherapy

Torben Rixecker, Stephan Stilgenbauer
2020-08-16

Allogeneic hematopoietic cell transplantation for patients with TP53 mutant or deleted chronic lymphocytic leukemia: Results of a prospective observational study

Johannes Schetelig, Jan M Middeke, Christopher P Fox, Nicolaus Kröger, Peter Dreger, Stephan Stilgenbauer
2020-09-01

Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial

Barbara Eichhorst, Stephan Stilgenbauer, Carsten Utoft Niemann
2020-09-21

Non-canonical effector functions of the T-memory-like T-PLL cell are shaped by cooperative TCL1A and TCR signaling

Stephan Stilgenbauer
2020-09-02

Prolonged Course of COVID-19-Associated Pneumonia in a B-Cell Depleted Patient After Rituximab

Stephan Stilgenbauer
2020-09-29

Higher-order connections between stereotyped subsets: implications for improved patient classification in CLL

Andrea Visentin, Livio Trentin, Krzysztof Giannopoulos, Stephan Stilgenbauer, Gianluca Gaidano, Diane F. Jelinek, Renee C. Tschumper, Carsten Utoft Niemann, Aleksandar J Dimovski
2020-10-13

Four-Factor Score for Outcome of Ibrutinib Treatment in Chronic Lymphocytic Leukemia: Prognostic Model for Risk Group Definition

Stephan Stilgenbauer
2020-10-29

Venetoclax plus bendamustine-rituximab or bendamustine-obinutuzumab in chronic lymphocytic leukemia: final results of a phase 1b study (GO28440)

Barbara Eichhorst, Stephan Stilgenbauer
2020-12-10

No increased bleeding events in patients with relapsed chronic lymphocytic leukemia and indolent non-Hodgkin lymphoma treated with idelalisib

Stephan Stilgenbauer
2020-12-11

U-RT1 - A new model for Richter transformation

Stephan Stilgenbauer
2020-12-09

Role of Specific B-Cell Receptor Antigens in Lymphomagenesis

Stephan Stilgenbauer
2020-04-28

Renal AA amyloidosis leading to early diagnosis and treatment of takayasu arteritis: a case report and review of the literature

Moritz Bewarder, Stephan Stilgenbauer
2020-05-01

DNA methylation of chronic lymphocytic leukemia with differential response to chemotherapy

Deyan Y Yosifov, Daniel Mertens, Stephan Stilgenbauer
2020-05-07

Clinical activity of abemaciclib in patients with relapsed or refractory mantle cell lymphoma - a phase II study

P Kellie Turner, Stephan Stilgenbauer, Catherine Thieblemont
2020-05-15

Feasibility and safety of CD19 CAR T cell treatment for B-cell lymphoma relapse after allogeneic hematopoietic stem cell transplantation

Stephan Stilgenbauer
2020-06-29

COVID-19 among fit patients with CLL treated with venetoclax-based combinations

Moritz Fürstenau, Clemens Wendtner, Carsten Utoft Niemann, Barbara Eichhorst, Stephan Stilgenbauer
2020-07-16

Identification of the atypically modified autoantigen Ars2 as the target of B-cell receptors from activated B cell-type diffuse large B-cell lymphoma

Sylvia Hartmann, Stephan Stilgenbauer, Michael Pfreundschuh
2020-01-31

BIRC3 mutations in chronic lymphocytic leukemia - uncommon and unfavorable

Stephan Stilgenbauer
2020-02-05

Revolution of Chronic Lymphocytic Leukemia Therapy: the Chemo-Free Treatment Paradigm

Stephan Stilgenbauer
2020-02-10

Prognostic model for newly diagnosed CLL patients in Binet stage A: results of the multicenter, prospective CLL1 trial of the German CLL study group

Barbara Eichhorst, Stephan Stilgenbauer, Jasmin Bahlo, Ursula Vehling-Kaiser
2020-02-11

IGLV3-21*01 is an inherited risk factor for CLL through the acquisition of a single-point mutation enabling autonomous BCR signaling

Cornelis Van Bergen, Christian E Busse, Massimo Degano, Axel Ronald Schulz, Hedda Wardemann, Stephan Stilgenbauer
2020-02-18

Early treatment with FCR versus watch and wait in patients with stage Binet A high-risk chronic lymphocytic leukemia (CLL): a randomized phase 3 trial

Othman Al-Sawaf, Barbara Eichhorst, Stephan Stilgenbauer, Jasmin Bahlo
2020-01-27

Long Term Follow-up Data and Health-Related Quality of Life in Frontline Therapy of Fit Patients Treated With FCR Versus BR (CLL10 Trial of the GCLLSG)

Barbara Eichhorst, Stephan Stilgenbauer, Jasmin Bahlo, Ursula Vehling-Kaiser
2020-02-27

Bendamustine, followed by ofatumumab and ibrutinib in chronic lymphocytic leukemia (CLL2-BIO): primary endpoint analysis of a multicentre, open-label phase-II trial

Barbara Eichhorst, Stephan Stilgenbauer, Jasmin Bahlo, Ursula Vehling-Kaiser
2020-03-05

Combining ibrutinib and checkpoint blockade improves CD8+ T-cell function and control of chronic lymphocytic leukemia in Em-TCL1 mice

Stephan Stilgenbauer
2020-03-17

Non-catalytic Bruton's tyrosine kinase activates PLCγ2 variants mediating ibrutinib resistance in human chronic lymphocytic leukemia cells

Peter Gierschik, Stephan Stilgenbauer
2020-03-18

Methylome-based cell-of-origin modeling (Methyl-COOM) identifies aberrant expression of immune regulatory molecules in CLL

Daniel B Lipka, Naveed Ishaque, Stephan Stilgenbauer
2020-03-23

Prognostic and predictive impact of genetic markers in patients with CLL treated with obinutuzumab and venetoclax

Barbara Eichhorst, Stephan Stilgenbauer, Jasmin Bahlo
2020-04-08

International Prognostic Score for Asymptomatic Early-stage Chronic Lymphocytic Leukemia

Stephan Stilgenbauer, Jasmin Bahlo, Franco Cavalli, Kari G Rabe, Emili Montserrat
2020-04-09

Comparative analysis of targeted next-generation sequencing panels for the detection of gene mutations in chronic lymphocytic leukemia: an ERIC multi-center study

Stephan Stilgenbauer
2020-04-16

Characterization of an HLA-restricted and human cytomegalovirus-specific antibody repertoire with therapeutic potential

Stephan Stilgenbauer
2020-12-01

Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial

Andreas Rosenwald, Harald Holte, Stephan Stilgenbauer, Michael Pfreundschuh

Human - wd:Q47158807

Welcome to Inventaire

la biblioteca dels teus amics i comunitats

saber més